Descriptor in English: | Axitinib |
Descriptor in Spanish: | Axitinib |
Descriptor in Portuguese: | Axitinibe |
Descriptor in French: | Axitinib |
Entry term(s): |
AG 013736 AG-013736 AG013736 Inlyta |
Tree number(s): |
D02.065.277.051 D02.241.223.100.100.115 D02.455.426.559.389.127.085.093 D03.383.129.539.487.065 D03.633.100.449.065 |
Scope note: | A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA. |
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
History Note: | 2019 (2005) |
DeCS UI: | 57757 |
Descriptor UI: | D000077784 |
Date Established: | 2019/01/01 |
Date of Entry: | 2018/07/09 |
Revision Date: | 2018/05/21 |
-
-
CHEMICALS AND DRUGS
Organic Chemicals [D02]Organic Chemicals -
CHEMICALS AND DRUGS
Organic Chemicals [D02]Organic Chemicals -
CHEMICALS AND DRUGS
Organic Chemicals [D02]Organic Chemicals -
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds -
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds
|
Axitinib
- Preferred
AG 013736
- Narrower
Inlyta
- Narrower
Concept UI |
M0489638 |
Scope note | A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA. |
Preferred term | Axitinib |
Concept UI |
M0496201 |
Preferred term | AG 013736 |
Entry term(s) |
AG-013736 AG013736 |
Concept UI |
M0578346 |
Preferred term | Inlyta |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey